TrialJournal of clinical pharmacology2019

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Manoli Vourvahis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.